Palivizumab

Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV) . Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice[1].

Product Specifications

CAS Number

[188039-54-5]

Product Name Alternative

MEDI 493

UNSPSC

12352203

Target

RSV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/palivizumab.html

Purity

99.63

Solubility

H2O

Smiles

[Palivizumab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]Johnson S, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176 (5) :1215-24. |[2]Jacobino SR, et al. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. MAbs. 2018 Apr;10 (3) :453-462. |[3]Piedimonte G, et al. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res. 2000 Mar;47 (3) :351-6.